1BT Stock Overview
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Enlivex Therapeutics Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.70 |
52 Week High | US$3.84 |
52 Week Low | US$1.20 |
Beta | 1.0 |
1 Month Change | 26.71% |
3 Month Change | 189.06% |
1 Year Change | 15.19% |
3 Year Change | -67.26% |
5 Year Change | n/a |
Change since IPO | -62.96% |
Recent News & Updates
Recent updates
Shareholder Returns
1BT | DE Biotechs | DE Market | |
---|---|---|---|
7D | 2.2% | -3.8% | 0.8% |
1Y | 15.2% | 23.4% | 6.2% |
Return vs Industry: 1BT underperformed the German Biotechs industry which returned 23.4% over the past year.
Return vs Market: 1BT exceeded the German Market which returned 6.2% over the past year.
Price Volatility
1BT volatility | |
---|---|
1BT Average Weekly Movement | 21.2% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.7% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1BT's share price has been volatile over the past 3 months.
Volatility Over Time: 1BT's weekly volatility has increased from 14% to 21% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Oren Hershkovitz | https://www.enlivex.com |
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors.
Enlivex Therapeutics Ltd. Fundamentals Summary
1BT fundamental statistics | |
---|---|
Market cap | €71.53m |
Earnings (TTM) | -€24.99m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs 1BT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1BT income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$27.16m |
Earnings | -US$27.16m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.46 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 1BT perform over the long term?
See historical performance and comparison